Literature DB >> 8317138

Therapies directed against endotoxin--has the time come?

Z M Quezado, W D Hoffman.   

Abstract

Mesh:

Substances:

Year:  1993        PMID: 8317138      PMCID: PMC1022085     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


× No keyword cloud information.
  8 in total

Review 1.  Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal.

Authors:  J D Baumgartner
Journal:  Infect Dis Clin North Am       Date:  1991-12       Impact factor: 5.982

Review 2.  Monoclonal antibodies to endotoxin in the management of sepsis.

Authors:  K C Fang
Journal:  West J Med       Date:  1993-04

3.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

4.  Endotoxemia in human septic shock.

Authors:  R L Danner; R J Elin; J M Hosseini; R A Wesley; J M Reilly; J E Parillo
Journal:  Chest       Date:  1991-01       Impact factor: 9.410

5.  A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.

Authors:  R L Greenman; R M Schein; M A Martin; R P Wenzel; N R MacIntyre; G Emmanuel; H Chmel; R B Kohler; M McCarthy; J Plouffe
Journal:  JAMA       Date:  1991-08-28       Impact factor: 56.272

6.  Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents.

Authors:  G D Martich; R L Danner; M Ceska; A F Suffredini
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

7.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.

Authors:  C Natanson; P W Eichenholz; R L Danner; P Q Eichacker; W D Hoffman; G C Kuo; S M Banks; T J MacVittie; J E Parrillo
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

8.  Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies.

Authors:  J D Baumgartner; D Heumann; J Gerain; P Weinbreck; G E Grau; M P Glauser
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.